ClinicalTrials.gg
CompletedNCT01724177Updated May 29, 2018Results posted

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

A Phase 2 interventional study of Lenalidomide in Adult T-Cell Leukemia-Lymphoma, sponsored by Celgene. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-05-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan — none open to participants now, 2 under way, none of them phase 3. Leukemia-Lymphoma, Adult T-Cell · Japan.

Enrollment
7th of 10
26 · median 36
Started
2012
the only one that year
Phase 2
4 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Celgene

Among the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan, this one is the 7th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 7th registered.

Leukemia-Lymphoma, Adult T-Cell

31 studies on the registry are indexed under Leukemia-Lymphoma, Adult T-Cell; 5 are open to participants now.

Browse Leukemia-Lymphoma, Adult T-Cell studies →

Open to participants now

None of the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan is open now. The open studies under Leukemia-Lymphoma, Adult T-Cell, anywhere →

Who these studies take

Of the 5 Leukemia-Lymphoma, Adult T-Cell studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan as a file.
02

Study summary

To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.

03

Conditions studied

  • Adult T-Cell Leukemia-Lymphoma

Keywords

  • Lenalidomide
  • ATL
  • ATLL
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign the
  • Aged 20 years or older (at the time of signing the informed consent)
  • Have a documented diagnosis of either: acute-, lymphoma-, or unfavorable chronic-type adult T-cell leukemia-lymphoma
  • Have received ≥1 prior anti-adult T-cell leukemia-lymphoma therapy, have achieved stable disease or better on their immediately prior therapy and have or progressed at the time of obtaining signed informed consent
  • Subjects for whom at least 1 (measurable lesion of computed tomography scan, peripheral blood or skin lesion) is confirmed in the lesion assessment before registration
  • Have an performance status of 0 to 2 at registration
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan

Exclusion criteria

Exclusion Criteria:

  • Have a history of central nervous system involvement or present with central nervous system symptoms, and are diagnosed with central nervous system lymphoma by cerebrospinal fluid cytology examination, head computed tomography scan or brain magnetic resonance imaging during the screening
  • Are pregnant or lactating
  • Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. Examples of such medical condition are, but are not limited to, as follows:

    • Uncontrolled diabetes mellitus as defined by the investigator or sub-investigator
    • Chronic congestive heart failure ( Class III or IV)
    • Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
    • cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia (subjects with controlled atrial fibrillation that is asymptomatic are eligible for this study)
    • Major surgery within 28 days of the start of study treatment
  • Exhibit grade 4 neurological disorders
  • Patients who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic prophylaxis.
  • Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs
  • Known positivity
  • Have surface antigen-positive, or virus anti-body positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B virus deoxyribonucleic acid test should be performed and if positive the subject will be excluded
  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  • Have a history of allogenic stem cell transplantation
  • Have received stem cell transplantation within 12 weeks (84 days) of the start of study treatment
  • Have previously used lenalidomide
  • Have a history of desquamating (blistering) rash while taking thalidomide
  • Have received any drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication
  • Have received any antibody agents within 12 weeks (84 days) of the start of study medication
  • Have received chemotherapeutic agents or immunomodulatory drugs for the treatment of adult T-cell leukemia-lymphoma within 4 weeks (28 days) of the start of study treatment
  • Have received radiotherapy within 4 weeks (28 days) of the start of study treatment
  • Have a history or complication of another malignant tumor other than adult T-cell leukemia-lymphoma and the following malignant tumors, unless the patients have been free of the disease for 5 years or longer

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Cervical carcinoma in situ
    • Carcinoma in situ of the breast
    • An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
    • Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
  • Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the registration;

    • : \< 1,200/µL
    • count: \< 75,000/µL
    • Serum /glutamyl oxaloacetic transaminase or alanine aminotransferase/glutamyl pyruvic transaminase: > 3 times the
    • level: > 1.5 times the upper limit of normal
    • : \< 60 mL/min
  • Any condition that confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity

    Drug: Lenalidomide

Interventions

  • 25 mg of Lenalidomide administered orally once daily

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)

    ORR is a Complete Response (CR) + Complete Response unconfirmed (CRu) + Partial Response (PR). A CR requires that target lesions have regressed to normal; nodal non-target lesions have regressed to normal; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are GR 0; peripheral blood is normal; Bone marrow (BM) infiltration is negative and no new lesions. A CRu requires the sum of the product diameters (SPD) of target lesions have decreased by at least 75% from baseline; nodal non-target lesions have regressed to normal size; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are Grade 0; peripheral blood is normal; BM infiltration is "negative" and no new lesions. A PR requires the SPD of target lesions has decreased by at least 50% from baseline; all nodal non-target lesions have regressed to normal or show no increase in size; all extranodal non-target lesions have disappeared

    Time frame: From day 1 of study treatment to date of first documented CR, CRU or PR; Up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks

Secondary outcomes

  1. Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC

    PFS was defined as the time from the first dose of study treatment to progressive disease (PD) or death due to any cause on study or within 28 days after study discontinuation, whichever occurred earlier.

    Time frame: From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks

  2. Kaplan-Meier Estimate of Time to Progression (TTP)

    Time to progression was calculated as the time from the first dosing of study treatment to the first documented PD and assessed by the ESEC

    Time frame: From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks

  3. Number of Participants With Treatment Emergent Adverse Events

    Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the start of study treatment and within 28 days after the last dose. Severity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Life-threatening and Grade 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks

  4. Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC

    The response duration in participants with an objective response was measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease (PD). For participants who did not progress during the study, DOR was censored at the last adequate response assessment not showing evidence of PD.

    Time frame: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks

  5. Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC

    The tumor control rate was measured for those with a response of Complete Remission, + CRu, + PR + Stable Disease (SD) in the EE population based on the best response.

    Time frame: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks

  6. Kaplan-Meier Estimate for Overall Survival

    Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive.

    Time frame: From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks

Other outcomes

  1. Time to Response

    Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR)

    Time frame: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks

07

Results

Posted Jan 5, 2016

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started26
Safety population26
Completed0
Not completed26
Withdrew: Adverse event8
Withdrew: Progressive disease or relapsed disease16
Withdrew: Nervous participant1
Withdrew: Serious adverse event related1

Outcome measures

PrimaryPercentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)

ORR is a Complete Response (CR) + Complete Response unconfirmed (CRu) + Partial Response (PR). A CR requires that target lesions have regressed to normal; nodal non-target lesions have regressed to normal; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are GR 0; peripheral blood is normal; Bone marrow (BM) infiltration is negative and no new lesions. A CRu requires the sum of the product diameters (SPD) of target lesions have decreased by at least 75% from baseline; nodal non-target lesions have regressed to normal size; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are Grade 0; peripheral blood is normal; BM infiltration is "negative" and no new lesions. A PR requires the SPD of target lesions has decreased by at least 50% from baseline; all nodal non-target lesions have regressed to normal or show no increase in size; all extranodal non-target lesions have disappeared

Time frame:
From day 1 of study treatment to date of first documented CR, CRU or PR; Up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)
percentage of participantsLenalidomide
Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)42.3 (23.352 to 63.082)
Statistical analysis
  • Lenalidomide · Exact Test · p = <0.0001 (A one sample binomial one sided exact test for the ORR (CR, CRu, or PR) was performed to provide the p-value (significance level: 0.05). The hypotheses of interest: H0: ORR ≤ 5% versus H1: ORR \> 5%)
SecondaryKaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC

PFS was defined as the time from the first dose of study treatment to progressive disease (PD) or death due to any cause on study or within 28 days after study discontinuation, whichever occurred earlier.

Time frame:
From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks
Reported as:
Median · weeks
Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC
weeksLenalidomide
Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC16.30 (8.100 to 24.000)
SecondaryKaplan-Meier Estimate of Time to Progression (TTP)

Time to progression was calculated as the time from the first dosing of study treatment to the first documented PD and assessed by the ESEC

Time frame:
From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimate of Time to Progression (TTP)
weeksLenalidomide
Kaplan-Meier Estimate of Time to Progression (TTP)16.30 (8.100 to 24.000)
SecondaryNumber of Participants With Treatment Emergent Adverse Events

Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the start of study treatment and within 28 days after the last dose. Severity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Life-threatening and Grade 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events
participantsLenalidomide
≥ 1 TEAE26
≥ 1 TEAE Related to Lenalidomide26
≥ 1 NCI CTCAE Grade (GR) 3 or Greater TEAE25
≥ 1 NCI CTCAE ≥ GR 3 TEAE Related to Lenalidomide25
≥ 1 Serious TEAE11
≥ 1 Serious TEAE Related to Lenalidomide9
≥ 1 TEAE Leading to Discontinuation8
≥ 1 Related TEAE Leading to Discontinuation8
≥ 1 TEAE Leading to Dose Reduction/Interruption17
≥ 1 related TEAE Leading to Decrease/Interruption17
≥ 1 TEAE Resulting in Death0
SecondaryKaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC

The response duration in participants with an objective response was measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease (PD). For participants who did not progress during the study, DOR was censored at the last adequate response assessment not showing evidence of PD.

Time frame:
From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks
Reported as:
Number · weeks
Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC
weeksLenalidomide
Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC24.10 (2.000 to NA)
Other pre-specifiedTime to Response

Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR)

Time frame:
From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
Reported as:
Median · weeks
Time to Response
weeksLenalidomide
Time to Response8.10 (7.9 to 16.0)
SecondaryPercentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC

The tumor control rate was measured for those with a response of Complete Remission, + CRu, + PR + Stable Disease (SD) in the EE population based on the best response.

Time frame:
From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC
percentage of participantsLenalidomide
Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC73.1 (52.213 to 88.427)
SecondaryKaplan-Meier Estimate for Overall Survival

Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive.

Time frame:
From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimate for Overall Survival
weeksLenalidomide
Kaplan-Meier Estimate for Overall Survival88.10 (43.000 to 109.100)

Adverse events

Collected over From the first day of lenalidomide treatment through 28 days after the last dose of lenalidomide. up to clinical cut-off date of 19 May 2017; maximum duration of study drug was 130.4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide22/26 (84.6%)11/26 (42.3%)26/26 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventLenalidomide
RashSkin and subcutaneous tissue disorders2/26
ThrombocytopeniaBlood and lymphatic system disorders2/26
Erythema multiformeSkin and subcutaneous tissue disorders1/26
Toxic skin eruptionSkin and subcutaneous tissue disorders1/26
AnaemiaBlood and lymphatic system disorders1/26
Non-cardiac chest painGeneral disorders1/26
PyrexiaGeneral disorders1/26
Enterocolitis infectiousInfections and infestations1/26
Meningitis bacterialInfections and infestations1/26
PneumoniaInfections and infestations1/26
Most frequent other events
Showing 10 of 73
Most frequent other events
EventLenalidomide
ThrombocytopeniaBlood and lymphatic system disorders20/26
NeutropeniaBlood and lymphatic system disorders19/26
LymphopeniaBlood and lymphatic system disorders18/26
AnaemiaBlood and lymphatic system disorders15/26
LeukopeniaBlood and lymphatic system disorders13/26
C-reactive protein increasedInvestigations11/26
HypoalbuminaemiaMetabolism and nutrition disorders9/26
HypoproteinaemiaMetabolism and nutrition disorders9/26
HyponatraemiaMetabolism and nutrition disorders9/26
HypophosphataemiaMetabolism and nutrition disorders9/26

Baseline characteristics

Intent to treat population consisted of all participants enrolled independent of whether they received study treatment or not.

Age, Continuous
Age, Continuous(years)Lenalidomide
Mean67.5 ± 7.20
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female12
Male14
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenalidomide
0 = Fully Active13
1 = Restrictive but Ambulatory9
2 = Ambulatory but Unable to Work4
3 = Limited Self-Care0
08

Study locations

18 sites
  • Nagoya City University Hospital
    Nagoya, Aichi 467-8602, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Ehime University Hospital
    Toon, Ehime 791-0295, Japan
  • Iwate Medical University Hospital
    Morioka, Iwate 020-8505, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Sasebo City General Hospital
    Sasebo, Nagasaki 857-8511, Japan
  • Heart Life Hospital
    Nakagami, Okinawa 901-2492, Japan
  • Shimane University Hospital
    Izumo, Shimane 693-8501, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Imamura Bunin Hospital
    Kagoshima, 890-0064, Japan
  • Kagoshima University Medical and Dental Hospital
    Kagoshima, 890-8520, Japan
  • National Hospital Organization Kagoshima Medical Center
    Kagoshima, 892-0853, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • The Japanese Red Cross Nagasaki Genbaku Hospital
    Nagasaki, 852-8511, Japan
  • Oita Prefectual Hospital
    Oita, 870-8511, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
09

References and documents

Publications

  • Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol. 2016 Dec;34(34):4086-4093. doi: 10.1200/JCO.2016.67.7732. Epub 2016 Sep 30. PubMed 27621400 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Nov 2014, 24 months.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2012
First posted
Nov 9, 2012
StartActual
Nov 12, 2012
Primary completionActual
Nov 20, 2014
CompletionActual
Mar 21, 2017
Results first posted
Jan 5, 2016
Last update
May 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01724177
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 9, 2012
Start date
Nov 12, 2012
Primary completion
Nov 20, 2014
Completion
Mar 21, 2017
Results posted
Jan 5, 2016
Last update
May 29, 2018

Study contacts

Toru Sasaki
study director · Celgene K.K.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion